Ferring and Igenomix Collaborate to Advance Care in Reproductive Medicine and Maternal Health
Ferring Pharmaceuticals and Igenomix today announced a two-year research collaboration aimed at the discovery of novel targets and disease mechanisms in infertility and pregnancy-related conditions, including preeclampsia, with the goal of developing innovative diagnostic and therapeutic strategies in these areas of high unmet need.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200603005784/en/
A new research hub will be created in Boston, bringing together scientists and expertise from both companies. The hub will focus on investigating molecular signatures, developing novel functional genomic systems and creating translational tools to study for embryo implantation, endometrial microbiome interaction and decidualization biology to drive innovative solutions for patients.
“Today, 1 in 6 couples worldwide are affected by fertility issues, with embryo implantation being a critical step to improving success rates in assisted reproduction technologies (ART) such as IVF. Furthermore, between 3 and 5% of all pregnancies are affected by preeclampsia,1 a severe complication which increases the morbidity and mortality of both mother and baby, said Joan-Carles Arce, Senior Vice President of Reproductive Medicine and Maternal Health, Ferring. Through this collaboration, we aim to advance diagnostic testing and the discovery of candidate drug targets in these areas of high unmet need and ultimately help more people build healthy families worldwide.”
“This new research hub will connect Igenomix’s unique diagnostic capabilities with Ferring’s deep therapeutic expertise, said Professor Carlos Simón, Head of Scientific Board of Igenomix Foundation and Project Lead for the new hub. We believe this collaboration will accelerate scientific findings and improve conception rates at a time when significant progress is needed in preimplantation science to help more women and families experience healthy pregnancies.”
ENDS
About Fertility Issues
The World Health Organization defines infertility as a disease of the reproductive system defined by the failure to achieve a clinical pregnancy after 12 months or more of regular unprotected sexual intercourse. Today, 1 in 6 couples worldwide are affected by fertility issues. Assisted Reproductive Technologies (ART) such as In Vitro Fertilisation (IVF) and Intracytoplasmic Sperm Injection (ICSI) can help couples who have problems conceiving naturally.
About Preeclampsia
Preeclampsia is a common and severe complication of pregnancy characterised by high blood pressure and multiple organ failure. It affects between 3% and 5% of all pregnancies in the US.1 There is a significant unmet need for an effective treatment for preeclampsia; currently the only ‘treatment’ is delivery of the baby.
Preeclampsia is responsible for approximately 20% of all preterm births2 and increases the morbidity and mortality of both mother and baby, especially in developing countries. An effective treatment would bring significant improvements in global infant and maternal health.
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.
Learn more at www.ferring.com, or connect with us on Twitter, Facebook, Instagram, LinkedIn and YouTube.
About Igenomix
Igenomix is a biotech company based in Valencia, Spain, specialized in reproductive genetics. Its expertise in fertility and its advanced research capacity situates the company as a worldwide referent in this area. Igenomix has 23 laboratories across the world and employs more than 400 professionals. Since the company launch in 2010, Igenomix has published more than 450 scientific papers and its communications have taken place during high level congresses such as ESHRE (European Society of Human Reproduction) or ASRM (American Society for Reproductive Medicine). Igenomix researchers have received numerous awards recognizing research and many of them share their knowledge and knowhow in leading US universities such as Stanford or Harvard.
References:
- CDC High Blood Pressure During Pregnancy 2020. Available at: https://www.cdc.gov/bloodpressure/pregnancy.htm
- Preeclampsia Foundation. FAQs. 2018. Available at: https://www.preeclampsia.org/faqs
# # #
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200603005784/en/
Contact information
Bhavin Vaid
Head of Corporate Communications
+41 58 301 0952 (direct)
+41 79 191 0632 (mobile)
bhavin.vaid@ferring.com
Lindsey Rodger
Senior Manager, Corporate Communications
+41 58 451 4023 (direct)
+41 79 191 0486 (mobile)
lindsey.rodger@ferring.com
Dulce Iborra
+34 647 942 875
dulce@laembajadora.es
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alpha’s latest report explores the impact of retail investors on fund finance provision17.9.2025 12:00:00 EEST | Press release
Alpha Group International plc (LON:ALPH) today announced the launch of its latest Lender Book Report, exploring and analysing the latest fund finance market trends. What does retail investment mean for subscription lines? Private capital funds, once the reserve of institutions such as pension funds and sovereign wealth funds, are rapidly opening up to a wider base of potential investors. Indeed, last month saw President Trump issue an executive order calling for expanded access to private equity and other alternative investments for 401(k) plans and their participants. While the push to open up private capital markets will undoubtedly see an influx of capital coming from new investor types, it also throws up a whole host of ramifications that need to be addressed. One of which is the impact on fund financing, namely subscription line loans. Traditionally, these facilities are secured against capital commitments from institutional investors into an alternative asset manager’s closed-end
LatticeFlow AI Sets a New Standard for AI Governance With Evidence-Based Technical Assessments17.9.2025 11:51:00 EEST | Press release
LatticeFlow AI, the Swiss deep-tech company advancing trustworthy and compliant AI, today announced the Early Access Program for AI GO!, the first platform that enables AI Governance Operations through deep technical assessments. With this, LatticeFlow AI sets a new standard for AI governance and compliance, enabling organizations to accelerate their AI advantage. Traditional Governance, Risk and Compliance (GRC) systems, based on checklists, are insufficient to govern complex and rapidly evolving AI systems. LatticeFlow AI GO! provides rigorous, evidence-based assessments that uncover AI risks, generate audit-ready insights, and empower confident decision-making. The platform equips AI risk and compliance teams with the visibility and confidence they need to harness the full potential of GenAI applications, chatbots, and the latest LLMs. “The only way AI governance can work and scale is when it’s grounded in technical evidence,” said Petar Tsankov, CEO and Co-Founder of LatticeFlow AI
Seven2 and HRK LUNIS Announce Successful Double Closing17.9.2025 11:01:00 EEST | Press release
Seven2, a leading European private equity firm, and HRK LUNIS, one of the leading independent wealth managers in Germany, have successfully completed both the majority stake acquisition of HRK LUNIS by Seven2, announced in March of this year, and the merger with Grossbötzl, Schmitz & Partner, announced in April. The smooth approval process is a positive sign for the German wealth management market and underlines the stability of the sector. With the completed double closing, HRK LUNIS's client assets under management have increased to approximately €7.5 billion and the number of employees to 120. The acquisition of HRK LUNIS is Seven2’s first investment in Germany, marking a key strategic milestone to further expand the private equity firm's position in Europe. Together with Seven2, HRK LUNIS will continue its growth trajectory, further develop its product offering, and optimize its digital capabilities to drive maximum customer benefits. The company offers a broad and competitive rang
Quectel Appoints Natasha Barrios as Senior Vice President of Sales for EMEA Region17.9.2025 11:00:00 EEST | Press release
Quectel Wireless Solutions, an end-to-end global IoT solutions provider, is pleased to announce the appointment of Natasha Barrios as Senior Vice President of Sales for the EMEA region. Natasha transitions to the role from her position as Vice President of Sales for North America where she helped to shape Quectel’s North American sales strategy, delivering exponential revenue growth across the region and scaling the team tenfold since 2017. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917625759/en/ Quectel appoints Natasha Barrios as Senior Vice President of Sales for EMEA region As part of her new role in EMEA, Natasha will spearhead the strategy to expand the reach of Quectel’s comprehensive portfolio of IoT products and services and drive continued year-over-year sales growth in EMEA. Her leadership and methodology is grounded in Quectel’s values of dedication, preparation, focus, innovation and mutual success with c
ISN ® Partners with Esso Exploration Angola Limited to Advance Contractor Management17.9.2025 11:00:00 EEST | Press release
ISN, the global leader in contractor and supplier information management services, announced the expansion of ISNetworld to Esso Exploration Angola Limited, an ExxonMobil affiliate, specialized in oil exploration and production. Through this collaboration, ISN will support Esso Angola in streamlining contractor management and oversight, meeting local compliance requirements, and increasing visibility into worker-level training and competency. “ExxonMobil has been a trusted partner of ISN for many years, and we are excited to continue our relationship with the Esso Angola team,” said David Bibby, Vice President of Europe, MEA, and APAC Operations at ISN. “This next step gives ExxonMobil’s team the tools to help standardize operations internationally, and create safer, more efficient job sites around the globe.” Building on a relationship that spans more than two decades with ISN, Esso Angola will leverage tools and services, such as Training Qualification and the Online Training tool, t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom